The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 84 | 1.8x | 20.1x | Above average | |
Growth | 44 | -5.8% | 5.6% | Near average | |
Quality | 83 | 239.5% | 7.6% | Above average | |
Safety | 70 | 0.1x | 0.4x | Above average | |
Capital Return | 45 | 4.28% | 2.19% | Near average | |
Momentum | 33 | — | — | Below average | |
Sentiment | 35 | — | — | Near average |
Novo Nordisk A/S is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Novo Nordisk A/S shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Novo Nordisk stock witnessed a positive adjustment in the average price target by 5.32% to reach $49.5, despite a wave of credit rating downgrades by major banks such as Goldman Sachs and Deutsche Bank, which shifted to a neutral stance (Hold/Neutral). This divergence reflects an upward revision in price expectations alongside operational caution, as the stock is currently trading at $42, which is below even the lower end of the analysts' range ($45), indicating a valuation gap in favor of the upside.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.